mRNA for use in treatment of human genetic diseases
View Patent ↗Compositions for modulating the expression of a protein in a target cell comprising at least one RNA molecule which comprises at least one modification conferring stability to the RNA, as well as related methods, are disclosed.
1. A composition for delivery of mRNA for protein expression in a target cell, comprising at least one mRNA molecule comprising a sequence encoding a protein of interest and a 5′ untranslated region (UTR) comprising SEQ ID NO: 1, wherein SEQ ID NO: 1 enhances the expression of the protein of interest.
2. The composition of claim 1 , wherein said mRNA molecule further comprises a poly A tail.
3. The composition of claim 1 , wherein said mRNA molecule further comprises a Cap1 structure.
4. The composition of claim 1 , wherein said mRNA molecule further comprises a 3′ untranslated region (UTR).
5. The composition of claim 4 , wherein said 3′ UTR comprises a sequence encoding human growth hormone (hGH).
6. The composition of claim 5 , wherein said sequence encoding human growth hormone (hGH) comprises SEQ ID NO: 3.
7. The composition of claim 1 , wherein the protein of interest is ornithine carbamoyltransferase.
8. The composition of claim 1 , wherein the protein of interest is alpha galactosidase.
9. The composition of claim 1 , wherein the protein of interest is erythropoietin.
10. The composition of claim 1 , wherein the target cell is selected from hepatocytes, epithelial cells, hematopoietic cells, endothelial cells, lung cells, bone cells, stem cells, mesenchymal cells, neural cells, cardiac cells, adipocytes, vascular smooth muscle cells, cardiomyocytes, skeletal muscle cells, beta cells, pituitary cells, synovial lining cells, ovarian cells, testicular cells, fibroblasts, B cells, T cells, reticulocytes, leukocytes, granulocytes or tumor cells.
11. The composition of claim 1 , wherein the mRNA molecule comprises one or more nucleotide substitutions or modifications that enhance stability, translational capacity or diminish immunogenicity.
12. The composition of claim 11 , wherein the one or more nucleotide substitutions or modifications include the incorporation of pseudouridine.
13. The composition of claim 1 , wherein the composition further comprises a transfer vehicle.
14. The composition of claim 13 , wherein the transfer vehicle is a liposomal vesicle.